<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04172480</url>
  </required_header>
  <id_info>
    <org_study_id>ANRS RF 004</org_study_id>
    <nct_id>NCT04172480</nct_id>
  </id_info>
  <brief_title>HUSH Restriction in HIV Infected Patients</brief_title>
  <official_title>HUSH Restriction in HIV Infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      HIV eradication faces a major obstacle that is viral persistence in latent reservoir cells
      despite antiretroviral therapy. Epigenetic repression plays a central role in viral transgene
      latency and several epigenetic regulators have been involved in this process. Among them, the
      &quot;Human Silencing Hub&quot; or HUSH complex, composed of Tasor, MPP8 and periphilin, has been shown
      to recruit the H3K9me3 methyltransferase &quot;SET domain bifurcated 1&quot; (SETDB1) and is therefore
      responsible for genes' epigenetic repression. Our recent results highlight the ability of Vpx
      from HIV-2/SIVsmm to counteract HUSH and to reactivate latent viruses in a latency model. We
      propose here to study HUSH activity along pathogenesis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Viremia</measure>
    <time_frame>Baseline</time_frame>
    <description>Intracellular HIV RNA load expressed in number of copies / ml</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total HIV DNA and integrated HIV DNA</measure>
    <time_frame>Baseline</time_frame>
    <description>Quantification by qPCR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hush activity</measure>
    <time_frame>Baseline</time_frame>
    <description>Transcription rate of cellular genes targeted by HUSH by qRT-PCR</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>acute HIV1 infection</arm_group_label>
    <description>Patient infected by HIV1, prior treatment initiation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>chronic HIV1 infection</arm_group_label>
    <description>Patient infected by HIV1, untreated or without treatment since at least 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV2 infection</arm_group_label>
    <description>Patient infected by HIV2, untreated or without treatment since at least 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <description>Peripheral blood sampling on EDTA</description>
    <arm_group_label>HIV2 infection</arm_group_label>
    <arm_group_label>acute HIV1 infection</arm_group_label>
    <arm_group_label>chronic HIV1 infection</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      PBMC conserved in RLT Buffer for viral DNA and RNA extraction
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Population infected either by HIV1 or HIV2
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria for group 1:

          -  Symptomatic or asymptomatic acute HIV1 infection

          -  Age above 15 years old

          -  No ARV treatment prior inclusion (excepted as prophylaxis pre or post exposure)

        Inclusion Criteria for group 2:

          -  Chronic HIV1 infection

          -  Age above 18 years old

          -  No ARV treatment since at least 3 month (regardless the reason)

        Inclusion Criteria for group 3:

          -  HIV2 Infection

          -  Age above 18 years old

          -  No ARV treatment since at least 3 month (regardless the reason)

        Exclusion Criteria for all groups:

          -  HIV1 and HIV2 co-infection

          -  Evolutive intercurrent pathology, in particular active co-infection (i.e. HBV, HCV,
             tuberculosis, HTLV1)

          -  Life-threatening pathology
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hôpital Bicêtre</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antoine CHERET, MD</last_name>
      <phone>1 45 21 25 77</phone>
      <phone_ext>33</phone_ext>
      <email>antoine.cheret@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôtel-Dieu</name>
      <address>
        <city>Paris</city>
        <zip>75004</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Paul VIARD, Pr</last_name>
      <phone>1 42 34 88 36</phone>
      <phone_ext>33</phone_ext>
      <email>jean-paul.viard@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claudine DUVIVIER, MD</last_name>
      <phone>1 44 38 17 42</phone>
      <phone_ext>33</phone_ext>
      <email>duvivier@nck.aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 19, 2019</study_first_submitted>
  <study_first_submitted_qc>November 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 21, 2019</study_first_posted>
  <last_update_submitted>November 19, 2019</last_update_submitted>
  <last_update_submitted_qc>November 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

